Shots:

• The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF for the treatment of multiple solid tumors. oxMIF combines with CDx for precise detection and targeted treatment
• Both companies will combine their expertise in drug discovery and manufacturing to develop the mAb product into the clinic
• OncoOne is expected to initiate P-I clinical trials for its ON203 as a therapeutic program & ON102 as a companion radio-labeled diagnostic in 2023

­Ref: PRNewswire | Image: GenScript ProBio